Company Encyclopedia
View More
name
Anika Therap
ANIK.US
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company’s joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions.
1.946 T
ANIK.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking134/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-8.73%D
    • Profit Margin-29.29%E
    • Gross Margin56.02%B
  • Growth ScoreB
    • Revenue YoY30.55%A
    • Net Profit YoY66.12%A
    • Total Assets YoY-18.14%E
    • Net Assets YoY-18.38%E
  • Cash ScoreC
    • Cash Flow Margin-341.45%D
    • OCF YoY30.55%A
  • Operating ScoreC
    • Turnover0.54C
  • Debt ScoreA
    • Gearing Ratio22.50%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Anika Therapeutics (NASDAQ:ANIK) Upgraded at Wall Street Zen

    Wall Street Zen upgraded Anika Therapeutics (NASDAQ:ANIK) from a "hold" to a "buy" rating. Barrington Research raised its price target from $15 to $16, while Weiss Ratings maintained a "sell (d-)" rating. The stock opened at $9.85, with a market cap of $142.02 million. Anika reported $0.04 EPS, beating estimates, and had revenue of $27.82 million. Institutional investors hold 91.53% of the stock. Analysts currently rate it as a "Moderate Buy" with a consensus price target of $18.50.

    Market Beat·
    US
    ANIK
    +0.21%
    Market Beat·
    US
    ANIK
    +0.21%

    Anika Therapeutics’ Earnings Call: Growth Amid Challenges

    Anika Therapeutics held its Q3 earnings call, revealing a mixed sentiment with 22% growth in Commercial Channel revenue, driven by the Integrity product line and international expansion. Despite a 6% overall revenue decline due to pricing pressures, the company achieved significant milestones, including a successful PMA submission for Hyalofast and surpassing 1 million Cingal injections. Anika reported cost structure improvements, but faced challenges in the OEM channel and Hyalofast study. The company maintains its full-year guidance and announced a $15 million share repurchase program, reflecting its commitment to growth and financial stability.

    Tip Ranks·
    US
    ANIK
    +0.21%
    Tip Ranks·
    US
    ANIK
    +0.21%

    Anika Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

    Anika Therapeutics Inc reported a quarterly adjusted loss of 16 cents per share for the quarter ended September 30, an improvement from a loss of 25 cents per share in the same quarter last year. Revenue fell 28.2% to $27.82 million, slightly above analyst expectations. The company reported a total loss of $2.33 million. Despite a 2.4% rise in shares this quarter, they have lost 41.5% year-to-date. Analysts maintain a "strong buy" rating with a median 12-month price target of $15.50, 37.9% above the last closing price of $9.63.

    Reuters·
    US
    ANIK
    +0.21%
    Reuters·
    US
    ANIK
    +0.21%

    InTest Reports Third Quarter 2025 Results | INTT Stock News

    InTest Corporation reported its Q3 2025 results, with orders surging 34.2% year-over-year to $37.6 million, despite a 13.3% revenue decline to $26.2 million due to shipment delays. The company generated $3.5 million in cash from operations and reduced total debt by $6.2 million. Operating loss was $1.2 million, with a net loss of $0.9 million or $(0.08) per diluted share. The backlog increased by 30.1% to $49.3 million, reflecting strong demand in various sectors, including automotive and defense.

    StockTitan·
    US
    INTT
    +3.09%
    StockTitan·
    US
    INTT
    +3.09%

    Anika Therap | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 27.82 M

    LB filings·
    US
    ANIK
    +0.21%
    LB filings·
    US
    ANIK
    +0.21%
    © 2025 Longbridge｜Disclaimer